Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI) Stock Overview
Explore Karyopharm Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
38.1M
P/E Ratio
-0.54
EPS (TTM)
$-11.87
ROE
0.37%
KPTI Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Karyopharm Therapeutics Inc. (KPTI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 56.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $6.90.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.54 and a market capitalization of 38.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Richard A. Paulson
279
85 Wells Avenue, Newton, MA
2013